Pharma BD Deal Intelligence
A ~$200M bet on a Phase 3 oncology asset turned into a $600M+/year blockbuster (Treanda/Bendeka) that anchored Cephalon's oncology franchise and became a marquee asset in Teva's subsequent $6.8B Cephalon buyout.
Full analysis, sources & comparables →Cephalon signed a definitive merger agreement to acquire Salmedix for approximately $160 million cash plus up to $40 million in regulatory milestones, gaining…
The Pharma Letter reports Cephalon agreeing to buy Salmedix for $160 million, acquiring the lead candidate Treanda (bendamustine) for non-Hodgkin's lymphoma…
Bendamustine described as 'the new 46-year-old kid on the block' in B-cell malignancies—repositioning a 1960s German alkylator into a modern CLL/iNHL frontline…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Cephalon agrees to acquire Salmedix for $160M cash. Gains bendamustine (later Treanda) - became >$1B oncology blockbuster.
A ~$200M bet on a Phase 3 oncology asset turned into a $600M+/year blockbuster (Treanda/Bendeka) that anchored Cephalon's oncology franchise and became a marquee asset in Teva's subsequent $6.8B Cephalon buyout.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cephalon Inc. / Salmedix, Inc. (this deal) | 2005 | $160M | 89 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
| Cephalon Inc. / Cell Therapeutics, Inc. | 2005 | $70M | 74 |
| Cephalon Inc. / Anesta Corp. | 2001 | $444M | 65 |
| Cephalon Inc. / Anesta Corp. | 2000 | $444M | 64 |
| Cephalon Inc. / Zeneus Holdings Limited (Zeneus Pharma) | 2005 | $360M | 63 |
← Browse all deals · How we score deals
More: 2005 deals · Cephalon Inc. deals